Immune thrombocytopaenic purpura following the second dose of Pfizer COVID-19 vaccine

Immune thrombocytopaenic purpura (ITP) is often a diagnosis of exclusion with presentations ranging widely from asymptomatic patients to those with life-threatening bleeding. Secondary ITP following vaccination is relatively uncommon and underdiagnosed as majority of patients remain asymptomatic. Ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Latef, Taroob, Howard, Leslie, Loke, Chandravathi, Tsui, Edison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Case Reports: Unusual association of diseases/symptoms
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442476/
http://dx.doi.org/10.1136/bcr-2022-249477
_version_ 1784782820727586816
author Latef, Taroob
Howard, Leslie
Loke, Chandravathi
Tsui, Edison
author_facet Latef, Taroob
Howard, Leslie
Loke, Chandravathi
Tsui, Edison
author_sort Latef, Taroob
collection PubMed
description Immune thrombocytopaenic purpura (ITP) is often a diagnosis of exclusion with presentations ranging widely from asymptomatic patients to those with life-threatening bleeding. Secondary ITP following vaccination is relatively uncommon and underdiagnosed as majority of patients remain asymptomatic. Cases of severe thrombocytopaenia associated with SARS-CoV-2 messenger RNA (ribonucleic acid) vaccinations have been described previously, mostly as isolated occurrences, and typically occurring following the first dose. Here we present a case of severe ITP associated with the second dose of the Pfizer-BioNTech/BNT16B2b2 mRNA vaccine and provide a review of the current literature.
format Online
Article
Text
id pubmed-9442476
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-94424762022-09-14 Immune thrombocytopaenic purpura following the second dose of Pfizer COVID-19 vaccine Latef, Taroob Howard, Leslie Loke, Chandravathi Tsui, Edison BMJ Case Rep Case Reports: Unusual association of diseases/symptoms Immune thrombocytopaenic purpura (ITP) is often a diagnosis of exclusion with presentations ranging widely from asymptomatic patients to those with life-threatening bleeding. Secondary ITP following vaccination is relatively uncommon and underdiagnosed as majority of patients remain asymptomatic. Cases of severe thrombocytopaenia associated with SARS-CoV-2 messenger RNA (ribonucleic acid) vaccinations have been described previously, mostly as isolated occurrences, and typically occurring following the first dose. Here we present a case of severe ITP associated with the second dose of the Pfizer-BioNTech/BNT16B2b2 mRNA vaccine and provide a review of the current literature. BMJ Publishing Group 2022-09-02 /pmc/articles/PMC9442476/ http://dx.doi.org/10.1136/bcr-2022-249477 Text en © BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.
spellingShingle Case Reports: Unusual association of diseases/symptoms
Latef, Taroob
Howard, Leslie
Loke, Chandravathi
Tsui, Edison
Immune thrombocytopaenic purpura following the second dose of Pfizer COVID-19 vaccine
title Immune thrombocytopaenic purpura following the second dose of Pfizer COVID-19 vaccine
title_full Immune thrombocytopaenic purpura following the second dose of Pfizer COVID-19 vaccine
title_fullStr Immune thrombocytopaenic purpura following the second dose of Pfizer COVID-19 vaccine
title_full_unstemmed Immune thrombocytopaenic purpura following the second dose of Pfizer COVID-19 vaccine
title_short Immune thrombocytopaenic purpura following the second dose of Pfizer COVID-19 vaccine
title_sort immune thrombocytopaenic purpura following the second dose of pfizer covid-19 vaccine
topic Case Reports: Unusual association of diseases/symptoms
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442476/
http://dx.doi.org/10.1136/bcr-2022-249477
work_keys_str_mv AT lateftaroob immunethrombocytopaenicpurpurafollowingtheseconddoseofpfizercovid19vaccine
AT howardleslie immunethrombocytopaenicpurpurafollowingtheseconddoseofpfizercovid19vaccine
AT lokechandravathi immunethrombocytopaenicpurpurafollowingtheseconddoseofpfizercovid19vaccine
AT tsuiedison immunethrombocytopaenicpurpurafollowingtheseconddoseofpfizercovid19vaccine

Ejemplares similares